Antibody-Drug ConjugatePH PHARMA

pH Pharma is developing multiple novel anticancer toxin categories that have unique mechanisms of action and are poised to improve the therapeutic index of existing toxins.

Development Status

  • pH Pharma initiated a toxin research program in Nov. 2016  to develop ADC cancer therapy.
  • 2 new toxins were in-licensed from Purdue University in Feb. 2018.
  • Our second novel toxin was patented in May 2019.
  • ADC candidate screening is on-going using novel antibodies and our proprietary toxin library.

What is an antibody-drug conjugate (ADC) ?

An antibody-drug conjugate (ADC) is a next generation targeted therapy for cancer using cancer-selective monoclonal antibodies linked with apoptosis-inducing drugs. It consists of antibodies, linkers, and toxins. After the internalization of the conjugate into the cancer cell, the linker detaches the toxin in order to induce cell death. The ADC market will continue to grow, reaching 22 billion USD in 2030.

Approved Therapies Projected Revenue: $22B+ by 2030

ADC Market Forecast (USD, billions)

Scientific Advisors

Henry Lowman

Ph. D.

  • Head of R&D, Triphase Accelerator Corporation
  • CSO, CytomX Therapeutics
  • Director, Protein Sciences, NGM Biopharmaceuticals
  • Director, Antibody Engineering, Genentech

Keith Wilson​

Ph. D.

  • Founder & CEO, Nalo Therapeutics
  • Founder & CEO, Trilo Therapeutics
  • CSO, Oxford BioTherapeutics
  • Director, Discovery, Abbvie

Mark Reynolds​

Ph. D.

  • Founder, First in Human LLC
  • Sr. Scientist, Genentech

Venita De Almeida

Ph. D.

  • Executive Director, Preclinical Devleopment, Sutro Biopharma
  • Scientific Researcher, Genentech

Jaewhan Song

Ph. D.

  • Professor, Department of Biochemistry, Yonsei University
  • Organizing Committee, Korean Society for Biochemistry and Molecular Biology

Name

Honorifix

  • detail